Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor Excretion

Clinical Chemistry
2006.0

Abstract

<jats:title>Abstract</jats:title><jats:p>Background: The heme precursors porphobilinogen (PBG) and 5-aminolevulinic acid (ALA) accumulate during overt crises of acute intermittent porphyria (AIP), and high excretion of these metabolites often continues in the asymptomatic phase.<jats:p>Methods: We measured concentrations of PBG and ALA and investigated the correlation between these metabolites in plasma and urine in 10 asymptomatic AIP carriers with high excretion and in 5 healthy individuals. We quantified plasma concentrations with an HPLC–mass spectrometric method and urine concentrations with ion-exchange chromatography.<jats:p>Results: The mean (SD) plasma concentrations of PBG and ALA in the AIP carriers were 3.1 (1.0) and 1.7 (0.7) μmol/L, respectively. The mean 8-h urinary excretion amounts of PBG and ALA in the AIP carriers were 102 (25) and 56 (18) μmol, respectively, whereas the corresponding values for healthy individuals were 2.9 (0.7) and 9.3 (1.2) μmol. The correlations between PBG and ALA values in plasma and urine of the AIP carriers were 0.678 and 0.856, respectively. The mean PBG/ALA ratio was ∼2.0 in both plasma and urine for the AIP carriers and 0.3 in urine for the healthy individuals. The renal clearance rates for PBG and ALA were 71 (15) and 70 (13) mL/min, respectively.<jats:p>Conclusions: The described HPLC-mass spectrometric method enabled characterization of variations in plasma PBG and ALA in AIP carriers during an 8-h period. The renal clearances were similar for both metabolites. This method could be used to monitor AIP patients during treatment.

Knowledge Graph

Similar Paper

Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor Excretion
Clinical Chemistry 2006.0
Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy
Journal of Medicinal Chemistry 2017.0
Design and synthesis of 5-aminolaevulinic acid/3-hydroxypyridinone conjugates for photodynamic therapy: enhancement of protoporphyrin IX production and photo-toxicity in tumor cells
MedChemComm 2016.0
Quantitation of homogentisic acid in normal human plasma
Journal of Chromatography B: Biomedical Sciences and Applications 1996.0
New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?
Biochemical Journal 2004.0
Improved Peptide Prodrugs of 5-ALA for PDT: Rationalization of Cellular Accumulation and Protoporphyrin IX Production by Direct Determination of Cellular Prodrug Uptake and Prodrug Metabolization
Journal of Medicinal Chemistry 2009.0
Developing urinary pyrrole–amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human
Archives of Toxicology 2021.0
A High-Performance Liquid Chromatography Method for the Detection of Diaminopimelic Acid in Urine
Analytical Biochemistry 2001.0
Plasma concentrations of p- and m-hydroxyphenylacetic acid and phenylacetic acid in humans
Journal of Chromatography B: Biomedical Sciences and Applications 1982.0
Relation of short-term pyridoxine-HCI supplementation to plasma vitamin B−6 vitamers and amino acid concentrations in young women
The American Journal of Clinical Nutrition 1992.0